ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag vaccine policy science policy cancer

Science, Policy Issues Put AIDS Vaccine On Slow Track
Myrna Watanabe | Nov 9, 1997 | 9 min read
The start of a clinical trial with an AIDS vaccine developed by French company Pasteur-Mérieux Connaught made front-page news in several major papers in September. The vaccine, composed of three HIV genes inserted into a canarypox vector, was administered to 420 human volunteers in a Phase II trial that tested the vaccine's safety and ability to provoke an immune response. Some researchers view the undertaking as one more trial of a technology that is unlikely to result in a useful compo
A shipping pallet of vaccines with Novavax's logo on it
FDA Authorizes Novavax COVID-19 Vaccine
Christie Wilcox, PhD | Jul 14, 2022 | 3 min read
Agency members express hope that the availability of a traditional, protein-based vaccine might convince holdouts to get vaccinated.
Policy Aspects Of Science Dominate 1994 AAAS Meeting
Franklin Hoke | Feb 6, 1994 | 4 min read
About 5,000 scientists are expected to attend the 1994 annual meeting of the American Association for the Advancement of Science, to be held in San Francisco February 18-23. * John Gibbons, Assistant to the President of the United States for Science and Technology, and Director of the Office of Science and Technology Policy: "Science, Technology, and the Clinton Administration." * "Health Care Reform and Advances in Medicine":
Biden Names Geneticist Eric Lander as Top Science Adviser
Max Kozlov | Jan 18, 2021 | 3 min read
If confirmed, Lander will head the Office of Science and Technology Policy, a position that President Donald Trump left vacant for 18 months at the beginning of his term.
Controversy Mounts Over Gene Patenting Policy
Scott Veggeberg | Apr 26, 1992 | 5 min read
Scientists in industry and academia foresee trouble as NIH persists in claiming ownership over partial sequences Date: April 27, 1992 The reviews from the scientific community remain mostly negative over the National Institutes of Health's patent application for a total of 2,722 partial human gene sequences. Academic researchers, who say they are mostly unaffected by the patenting process, nevertheless are appalled; and while some in the commercial sector of the biotech community now believe
Opinion: Ethical Boundaries Needed on the Uses of Synthetic DNA
John D. Loike and Robert Pollack | Mar 1, 2019 | 4 min read
A newly expanded genetic alphabet that includes four synthetic nucleotides highlights the need for strict boundaries on their use.
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Failed vaccine trial raises questions
Jef Akst | Jun 23, 2011 | 2 min read
In contrast to yesterday’s news about the success of an HPV vaccine program in Australia, an Indian trial of the vaccine is stoking unfounded fear among the public and exposing some questionable ethical standards.
Rewards of Risk
Megan Scudellari | Feb 1, 2011 | 7 min read
Secrets to scoring big money grants for innovative, out-of-the-box research
Support for use of animals in research
Susan Mayor | Apr 23, 2002 | 5 min read
The UK government has set out in full for the first time its policy on the use of animals in medical research.

Run a Search

ADVERTISEMENT